Preprint identifies cyclin C nuclear release and mitochondrial dysfunction as molecular signatures of MED13L syndrome

A preprint posted to bioRxiv investigates the molecular basis of MED13L syndrome, a rare neurodevelopmental disorder caused by heterozygous loss-of-function or missense variants in MED13L, which encodes a core component of the Mediator Kinase Module (MKM). The MKM is a regulatory sub-complex of the larger Mediator coactivator complex, which coordinates RNA polymerase II-driven transcription programmes controlling cellular metabolism, stress responses, and differentiation. MED13L syndrome is characterised by variable degrees of intellectual disability, developmental delay, neuromuscular dysfunction, and congenital structural anomalies, but the molecular mechanisms driving this clinical variability have not been well defined.

The preprint authors — who previously identified mitochondrial dysfunction and aberrant nuclear localisation of cyclin C (encoded by CCNC, another MKM component) in a single patient-derived cell line — now report these as consistent molecular signatures across multiple MED13L syndrome patient models. The findings suggest that cyclin C nuclear release and downstream mitochondrial dysfunction may be mechanistically central to MED13L syndrome pathophysiology rather than incidental observations.

The work is relevant to rare-disease researchers, clinical geneticists with patients carrying MED13L variants, and those studying Mediator complex biology more broadly. The preprint has not yet been peer reviewed.